New Independent Research Hub Launches for Eloralintide, Lilly’s Investigational Amylin Agonist

Eloralintide-Peptide.com brings Phase 2 and Phase 3 trial data, comparisons with semaglutide, tirzepatide, retatrutide and cagrilintide, and sourcing checks together in one place

Los Angeles, United States, November 9, 2026 -- Los Angeles, United States, 9th November – Eloralintide-Peptide.com, an independent research resource dedicated to eloralintide (LY3841136), launched today. The site gathers published trial results, registry updates, mechanism explainers and side-by-side comparisons so researchers can follow one of the most closely watched compounds in metabolic research without piecing it together from scattered sources.

Eloralintide is an investigational once-weekly selective amylin receptor agonist being developed by Eli Lilly and Company. Unlike GLP-1 medications such as semaglutide, it does not act on GLP-1 or GIP receptors. It targets the amylin pathway, the satiety signaling system involving the hormone co-released with insulin after a meal. The compound is not approved by the FDA or any other regulator.

What the hub covers

• Trial data: Phase 1 and Phase 2 results by dose arm, safety tables, and the ENLIGHTEN Phase 3 timeline. The Phase 2 trial, published in The Lancet in November 2025, enrolled 263 adults and reported mean weight changes of -9.5% to -20.1% at 48 weeks versus -0.4% on placebo. Phase 3 trials ENLIGHTEN-1 and ENLIGHTEN-6 began enrolling in February 2026, and no Phase 3 results have been reported.


• Mechanism: A plain-language explanation of amylin biology and of eloralintide’s reported selectivity for the AMY1R receptor subtype. The site separates cell-assay findings from outcomes in people.


• Comparisons: Dedicated pages on eloralintide versus cagrilintide, retatrutide and tirzepatide, with the mechanism difference first and trial numbers presented with their length, population and endpoint definitions. The site notes that no head-to-head trials exist, which limits every comparison.


• Research tools: A vial concentration calculator, a guide to reading certificates of analysis (COAs), and a library of reviewed lot certificates.


• Vendor checks: Dated reviews of research-compound suppliers against published criteria, including lot-level testing documentation, shipping terms and a rule against human treatment claims.


• Updates: Dated research notes and an email list for Phase 3 registry changes and trial readouts.

“ Eloralintide went from a quiet pipeline name to one of the most searched compounds in metabolic research in a matter of months, and the information out there hasn’t kept up. We built this site so every claim links to a paper, a registry record or a dated check, and so the limits of each comparison are stated plainly. ” said Daniel Rogers, Chief Researcher.

The website was designed and produced by All Star Digital, a digital marketing and AI Search agency.

About All Star Digital

All Star Digital is a Los Angeles-based digital marketing and SEO agency. Learn more at allstardigital.pro.

About Eloralintide Peptide

Eloralintide-Peptide.com is an independent publisher and is not affiliated with Eli Lilly and Company. All content is provided for research and informational purposes only. Eloralintide is investigational, nothing on the site is medical advice, and trial results describe an investigational drug in controlled studies, not any research product sold by a vendor.

Contact Info:
Name: Kyle Monaghan
Email: Send Email
Organization: Eloralintide Peptide
Phone: 3105589902
Website: https://eloralintide-peptide.com/

Release ID: 89208885

In the event of detecting errors, concerns, or irregularities in the content shared in this press release that require attention or if there is a need for a press release takedown, we kindly request that you inform us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your feedback within 8 hours and take necessary actions to resolve any identified issues diligently or guide you through the removal process. Providing accurate and dependable information is our utmost priority.